NIKKEI 225
39,040.39 +423.29 (+1.10%) HANG SENG
18,929.47 -266.13 (-1.39%) CRUDE OIL
77.15 -0.42 (-0.54%) GOLD FUTURES
2,372.60 -20.30 (-0.85%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,465.29 -469.14 (-0.85%)
HAE May 2024 95.000 put
| Previous close | 4.5000 |
| Open | 4.5000 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 95.00 |
| Expiry date | 2024-05-17 |
| Day's range | 4.5000 - 5.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
ZacksHere's Why You Should Buy Haemonetics (HAE) Stock Now
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
GuruFocus.comInsider Sale: EVP Josep Llorens Sells Shares of Haemonetics Corp (HAE)
Josep Llorens, Executive Vice President, Global Manufacturing at Haemonetics Corp (NYSE:HAE), executed a sale of 1,809 shares of the company on May 20, 2024.
PR NewswireHaemonetics Announces Proposed Convertible Senior Notes Offering
Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Haemonetics also expects to grant the initial purchasers of the notes an option to purchase up to an additional $
